Revolutionizing Ocular Drug Delivery: Role And Challenges Of Nanoemulgel Technology

Many ocular diseases are treated with conventional eye drops, but these suffer from poor drug retention and low bioavailability—typically under 5% of the instilled dose actually penetrates the eye’s tissues. Nanoemulgel technology, which marries nano-scale emulsions with a gel matrix, has emerged as a promising strategy to address these limitations. By incorporating sub-100 nm, drugloaded droplets into a mucoadhesive hydrogel, nanoemulgels can prolong the formulation’s residence time on the eye, sustain drug release, and enhance corneal drug penetration. This review provides a comprehensive examination of nanoemulgel formulation strategies for ocular drug delivery and explores their clinical applications. Key formulation factors are discussed, including methods for preparing nanoemulsions, choices of oils, surfactants and gelling agents, as well as characterization techniques. The paper also summarizes results from recent studies and clinical evaluations, which highlight improved therapeutic outcomes in conditions like glaucoma, dry eye disease, and ocular infections when nanoemulgels are used. The advantages of nanoemulgels— such as better patient compliance and higher efficacy—are weighed against the challenges they face, including formulation stability issues, sterility requirements, potential ocular irritation, and regulatory hurdles. Preclinical findings demonstrate that nanoemulgels can significantly enhance drug delivery to the eye, but further clinical trials and clear regulatory guidance are needed to translate this innovative platform into approved treatments. Overall, nanoemulgel technology shows great promise to transform ocular pharmacotherapy by bridging advances in nanomedicine with sustained-release gel systems.